Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 10/20 | 0.46 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572784 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL1908566 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059572 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059571 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL609953 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL597164 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL24404055 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18574633 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| Hydrochloric Acid SCHEMBL597844 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL7426879 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | claimed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | claimed |
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
| CN-103483236-B | Prepare method and the intermediate of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives | 诺华股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2016135751-A1 | NOVEL PROCESS FOR THE PREPARATION OF SACUBITRIL AND ITS INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-09-01 | — | — | WO | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| CN-103080077-B | Process for the preparation of intermediates for the manufacture of NEP inhibitors | NOVARTIS AG | 2015-06-10 | — | — | CN | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | MME, ACE, REN | GPR88 2990/4885SRR 535/4885PSAT1 286/4885 |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | MME, ACE, REN | GPR88 2990/4885SRR 535/4885PSAT1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.